Advancing Kv7 Channel Science and Drug Development
Xyzagen is proud to support the 2026 Kv7 Channels Symposium as a lanyard sponsor. This international meeting brings together researchers, drug developers, and industry leaders focused on advancing the understanding of Kv7 ion channels and their role in neurological disease.
The Kv7 Channels Symposium provides an important forum for discussing the latest discoveries in ion channel biology, translational research, and emerging therapeutic strategies targeting epilepsy, pain, and other neurological disorders. Xyzagen looks forward to connecting with fellow scientists and collaborators throughout the meeting.
Supporting the Future of Kv7 Therapeutics
Kv7 channel biology has long been an area of scientific focus for Xyzagen given that our founder was part of the team that brought Potiga to the market place and sold to Xenon their product Azetuklaner. Our team has extensive experience supporting CNS drug development through integrated pharmacokinetics, pharmacology, translational modeling, and bioanalytical services.
From early discovery through clinical development, we partner with biotechnology and pharmaceutical companies to help optimize drug candidates, answer complex PK questions, and generate the data needed to make informed development decisions.
As discussions continue around next-generation Kv7-targeted therapies, we look forward to exchanging ideas with researchers working to advance innovative treatments for neurological disorders.
Meet the Xyzagen Team
Whether you’re developing Kv7-targeted therapeutics, exploring translational pharmacology strategies, or looking for an experienced CRO and pharmacokinetics partner, our team is always happy to discuss your program and how we can help accelerate development.
Interested in scheduling a free consultation? Contact us to start the conversation.
About Xyzagen
Xyzagen is a boutique pharmacokinetics consultancy and contract research organization (CRO) providing integrated drug development support from early discovery through clinical development. Our services span pharmacology, in vivo PK, bioanalysis, biomarker development, clinical pharmacology, and model-informed drug development (MIDD), helping biotechnology and pharmaceutical companies make confident, data-driven development decisions. By combining senior scientific expertise with flexible, high-touch collaboration, we work as an extension of our clients’ teams to accelerate programs from candidate selection through regulatory submission.
